IDDF2018-ABS-0097 Genomic heterogeneity and clonal evolution of multifocal hepatocellular carcinoma. (8th June 2018)

• Record Type: Journal Article
• Authors: Xu, Lixia; He, Minghui; Dai, Zihao; Peng, Sui; Kuang, Ming
• Is Part Of: Gut. Volume 67(2018)Supplement 1
• Page Start: A296
• Page End: A296
• Publication Date: 2018-06-08
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-IDDFbestabstracts.6
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background: Hepatocellular carcinoma (HCC) often presents with multiple tumours within the liver. Although recent genomic studies evaluating intratumor heterogeneity, the identification of intrapatient heterogeneity (IPH) and its impact on targeted therapy for multifocal HCC remain unclear. We aimed to characterise genomic architecture, infer the clonal evolution of multifocal HCC, and explore whether genomic profiling could help select suitable patients for targeted therapy. Methods: 43 tumour samples from 11 multifocal HCC patients were employed for whole-genome sequencing, whole-exome sequencing and RNA sequencing. Somatic mutations, copy number alterations (CNAs), structural variations (SVs), hepatitis B virus integrations, as well as clonal evolution and druggable targets of each tumour were analysed. Results: We identified substantial IPH in mutational profiles, CNAs, SVs and clonal evolution among tumours separated by anatomical locations within the same patient. 41 out of 43 tumour samples in our study belong to intrahepatic metastasis. Phylogenetic analysis found that only 31% of the driver alterations were truncal events, indicating evident IPH and branched tumour evolution of multifocal HCCs. Moreover, only 23% of druggable alterations were mapped to trunks. Of note, sorafenib sensitive targets were identified in the trunk of only one out of five patients. Conclusions: Our study provided a detailed view of IPH and clonal evolution of multifocal HCC. Most tumours in our cohort belong to intrahepatic metastasis and follow the scenario of branched tumour evolution. Majority of druggable targets are non-truncal alterations, emphasising the importance of multiple-tumor-sampling of all foci from multifocal HCC patients for personalised targeted therapies.